Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 3 Race/ethnicity disparities in the use of biologic DMARDs among RA patients in Medicaid

From: Factors associated with initial or subsequent choice of biologic disease-modifying antirheumatic drugs for treatment of rheumatoid arthritis

Cohort group Race/ethnicity Total, n Biologic DMARD initiation/switch, n No biologic DMARD initiation/switch, n Adjusted OR (95% CI)
Odds of biologic DMARD initiationa
Early untreated RA, biologic-DMARD-naive group White, non-Hispanic 23,627 794 22,833 Ref
Black, non-Hispanic 13,531 275 13,256 0.59 (0.51, 0.68)
Other non-Hispanic 4824 133 4691 0.88 (0.72, 1.06)
Hispanic 9875 403 9472 1.24 (1.08, 1.42)
  Total 51,857 1605 50,252
Prevalent RA, biologic-DMARD-naive group White, non-Hispanic 25,537 2570 22,967 Ref
Black, non-Hispanic 11,171 759 10,412 0.71 (0.61, 0.74)
Other non-Hispanic 5950 521 5429 0.89 (0.81, 0.99)
Hispanic 10,853 1219 9634 1.08 (0.99, 1.17)
Total 53,511 5069 48,442
Odds of biologic DMARD switcha
Prevalent RA, prior biologic DMARD users White, non-Hispanic 4181 532 3649 Ref
Black, non-Hispanic 976 99 877 0.71 (0.55, 0.90)
Other non-Hispanic 836 98 738 1.08 (0.85, 1.41)
Hispanic 1670 192 1478 0.92 (0.76, 1.12)
  Total 7663 921 6742
  1. DMARD disease-modifying antirheumatic drug, RA rheumatoid arthritis. aAdjusted for demographics, data source, calendar year, comorbidities, history of medication use, and healthcare utilization in baseline period